Diaceutics PLC

Full Year 2024 trading results just announced! We are delighted to share a strong performance for FY 2024, reflecting our continued commitment to driving innovation and delivering value for our pharma and biotech partners and the positive outlook moving into 2025. Here are some key highlights, you can view the results in full at: https://lnkd.in/eWG9UmV4 ·??Revenue grows 39% on a constant currency basis to ￡32.2 million in FY 2024 ·??Order book of ￡24.9 million and ARR of ￡16.8 million at 31 December 2024 provides good visibility for continued strong growth in 2025 ·??23% growth in number of customer therapeutic brands working with and three new customer enterprise-wide engagements added in FY 2024 ·??Strong balance sheet with cash of ￡12.7 million ·??Successfully launched PMx solution and secured first commercial contract as a promotional partner with a leading biotech for the launch of a breakthrough oncology precision medicine in the US ·??New Pathology Engagement Liaison service (PEL) launched and first major customer contract win ·??Increased sales presence in US during FY 2024 and opened US HQ in January 2025 We are excited about the future as we continue to drive innovation in precision medicine and enable more patients to benefit from better treatment. #Diaceutics #PrecisionMedicine #Innovation #Healthcare #Results #FutureFocused #financials

Are you facing challenges in reaching and engaging relevant physicians for your precision medicine therapy? ? Research shows that only 16% of physicians rely on in-person interactions to learn about new treatments and biomarkers. Meanwhile, over 67% prefer digital channels to stay informed about novel treatments and biomarkers. A data-driven, omnichannel approach enables you to target and engage relevant physicians treating therapy-eligible patients with a timely educational message on your test or therapy, to drive testing rates and treatment adoption. Discover more in our next webinar, "Data-driven Targeting in Clinical Education: Engaging HCPs Within the Critical Treatment Window" on March 26, at 12:00 PM ET / 6:00 PM CET. Register here: https://lnkd.in/g8sgqpqw #Webinar #PrecisionMedicine

Just one week to go until our webinar, “Data-driven targeting in HCP education: Engaging physicians within the critical treatment decision window” on Wednesday, March 26th at 12:00 PM ET/6:00 PM CET. Gosia Leitch, VP of Engagement Solutions will be joined by Scott Phillips, VP of Real World Data, and our two guest speakers - leading pharma experts Sopheara Peoples, Senior Director, Head of Oncology (Digital, Data and Technology) at GSK and Gunjan Aggarwal, Executive Director (Insights & Decision Science), Novartis. Gain exclusive insights on: ??Why a digital-first strategy is essential for cutting through the noise in clinical education ??How real-world data-informed omnichannel strategies can engage physicians within 24 hours before a treatment decision is made ??Insights into the challenges of reaching and engaging physicians, and strategies that drive commercial launch success. Register today: https://lnkd.in/g8sgqpqw #Webinar #PrecisionMedicine

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics recently spoke at the annual Precision Med TRI-CON last week in San Diego, addressing access barriers in Liquid Biopsy Testing. Susanne’s talk, ‘From Exploratory to Mainstream; Overcoming Access Barriers in Liquid Biopsy Testing’, built on insights from our globally recognized Practice Gaps Paper, which revealed that 64.4% of advanced NSCLC patients do not receive the right treatment, and only 36.1% of newly diagnosed advanced NSCLC patients were found to be properly tested and treated. Despite advancements, 17% of patients are still being left behind due to challenges with their tissue biopsy samples. Sussanne discussed the barriers preventing liquid biopsy from becoming?standard part of clinical practice and emphasised the critical need for greater adoption in precision oncology. Susanne highlighted the steps needed to drive change, including the need for multiple biomarker testing to be firmly established in NSCLC. Learn more in the newly released ‘Recommendations Paper’ outlining actionable steps the industry can take to address operational, economic, and policy challenges in precision medicine. Download the recommendations paper here: https://lnkd.in/e7FnGF49

Tomorrow, our team will be in Philadelphia for the annual Pharma USA conference from 18-19th March. We are looking forward to connecting with industry leaders across commercial, medical affairs, patient engagement, and real-world data to discuss the latest strategies driving precision medicine adoption. Talk to our team at Pharma USA about our Engagement Solutions, enabling you to leverage real-world lab data from over 500 US Labs to precisely target and engage relevant HCPs within 24 hours of a biomarker-positive test result. Message us to book a meeting with our team. #REpharmaUSA #PrecisionMedicine ?

If you could reach and educate physicians at time of diagnosis, what impact would this have on therapy adoption? Slow uptake of tests is often due to a lack of awareness regarding the clinical utility of new biomarkers and associated therapies. DXRX Physician Engage leverages real-world lab data from our extensive lab database of over 500 US labs to precisely target and engage relevant physicians within 24 hours of a biomarker-positive test result. Our specialized precision medicine content writing experts create tailored, educational messages that captivate and engage target physicians, to enable informed treatment decisions. Download our flyer to learn more about how DXRX Physician Engage accelerates treatment adoption, and schedule a meeting with our solution experts at Pharma USA next week. Download flyer here: https://lnkd.in/eaTchi_9 #REpharmaUSA #PrecisionMedicine

Our team will be in Boston for the upcoming USCAP 2025 conference from March 22-27th, connecting with pathologists and industry experts to explore the latest advancements in biomarker testing, precision diagnostics, and real-world data insights. Message us to book a meeting with one of our solution experts to discover how we can help you drive biomarker adoption and accelerate commercialization success. #USCAP2025 #PrecisionMedicine #Pathology

We are delighted to announce that Sopheara Peoples, Senior Director and Head of Oncology (Digital, Data, and Technology) at GSK, will be joining us as a guest speaker for our upcoming webinar, “Data driven targeting in HCP education: Engaging physicians within critical treatment decision window" on March 26 at 12:00 PM ET / 6:00 PM CET. During this session, we'll explore: ??How a multi-modal data approach enables precise HCP targeting ??Why a digital-first strategy is essential for cutting through the noise in clinical education ??How real-world data-informed omnichannel strategies can engage physicians within 24 hours before a treatment decision is made ??Insights into the challenges of reaching and engaging physicians, and strategies that drive commercial launch success. Register here:?https://lnkd.in/g8sgqpqw #Webinar #BetterTestingBetterTreatment

This week, we held our real-world data webinar, 'Complexity to Clarity: Using Multi-Modal Data To Drive Commercial Success.' During this session, Scott Phillips, Vice President of Real World Data at Diaceutics, shared insights on how leveraging both lab and genetic data can refine precision medicine strategies to help pharma and biotech teams make smarter commercialization decisions, and discussed how this approach moves beyond traditional claims aggregation to overcome market complexities and improve patient outcomes. If you missed it, the webinar recording is available to watch here:?https://lnkd.in/eW-ddWST #Webinar #PrecisionMedicine?

2 days to go! 'A multidisciplinary approach to HRR testing in prostate cancer' ?? 13th March 2025 ?? 5:30pm CET Our next Lab Talk brings together an expert panel to discuss and share their point of views regarding the current approach to HRR testing in metastatic prostate cancer. Understand challenges experienced today with activating a HRR test during the prostate cancer patient journey and explore the evolving role of ctDNA in supporting HRR testing. Join our expert panel as they discuss real world scenarios and how their institutional multi-disciplinary approach has improved test activation for their metastatic prostate cancer patients. This session will highlight how a collaborative approach between a multidisciplinary team can be used to improve patient outcomes. Register now to find out more! https://lnkd.in/e3eu-PzH